{"id":45209,"date":"2022-06-17T14:01:39","date_gmt":"2022-06-17T12:01:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/microbiome-global-fmt-microbiome-drugs-market-report-2022-featuring-major-players-microbiome-therapeutics-seres-therapeutics-enterome-bioscience-second-genome-vedanta-biosciences-researchan\/"},"modified":"2022-06-17T14:01:39","modified_gmt":"2022-06-17T12:01:39","slug":"microbiome-global-fmt-microbiome-drugs-market-report-2022-featuring-major-players-microbiome-therapeutics-seres-therapeutics-enterome-bioscience-second-genome-vedanta-biosciences-researchan","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/microbiome-global-fmt-microbiome-drugs-market-report-2022-featuring-major-players-microbiome-therapeutics-seres-therapeutics-enterome-bioscience-second-genome-vedanta-biosciences-researchan\/","title":{"rendered":"Microbiome Global (FMT, Microbiome Drugs) Market Report 2022 Featuring Major Players – MicroBiome Therapeutics; Seres Therapeutics; Enterome Bioscience; Second Genome; Vedanta Biosciences – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Microbiome Global Market Report 2022: By Type, By Application, By Technology”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global microbiome market is expected to grow from $5.54 billion in 2021 to $6.18 billion in 2022 at a compound annual growth rate (CAGR) of 11.4%. The market is expected to reach $10.09 billion in 2026 at a CAGR of 13.1%.\n<\/p>\n

\nThe microbiome market consists of sales of microbiomes drugs and related services. Microbiome therapy aims at restoring balanced gut microbiota and is expected to decrease the risk of infection recurrence and greatly increase the quality of life of patients.\n<\/p>\n

\nThe main types of microbiomes are fecal microbiota transplantation (FMT) and microbiome drugs. The technique of transferring faecal bacteria and other germs from one healthy person to another is known as faecal microbiota transplantation, or stool transplantation. The different technologies include genomics, proteomics, metabolomics and is used in inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, others.\n<\/p>\n

\nThe increasing prevalence of inflammatory bowel disease (IBD) is a key factor driving the growth of the microbiome market. Inflammatory bowel disease (IBD) is a multifactorial and autoimmune infection group consisting of two major entities such as ulcerative colitis (UC) and Crohn’s disease (CD). Fecal microbiota transplantation (FMT) and probiotics were discovered as potential applications in many immune-mediated disorders, such as IBD, to restore microbial balance.\n<\/p>\n

\nThese microbial therapies have shown the potential to reduce both the dysbiotic condition and the development of inflammatory mediators, thereby enabling remission, particularly in UC. In 2019, approximately 1.6 million people in the United States suffered from untreatable inflammatory bowel disease (IBD), including Crohn’s or ulcerative colitis. Therefore, the increasing prevalence of inflammatory bowel disease (IBD) is expected to drive the growth of the microbiome market.\n<\/p>\n

\nThe high cost of microbial therapy is a key factor hampering the growth of the microbiome market. The price of fecal transplantation, a microbial therapy, may vary considerably depending on the delivery method used by users and where users receive it. Fecal microbiota transplant processes can charge around $600-$1,000 based on the method of treatment, area, insurance coverage and other variables. Therefore, the high cost of microbial therapy is expected to hinder the growth of the microbiome market.\n<\/p>\n

\nThe growing technological improvement is a major trend gaining popularity in the microbiome market. Major companies in the microbiome sector are focusing on developing advanced technology solutions for microbiomes. For instance, Seed, a new microbiome company, has introduced Probiotic and Prebiotic Daily Synbiotica for both females and males.\n<\/p>\n

\nThe Daily Synbiotic Seed is the first to follow a microbe-system strategy with strain-specific advantages beyond digestive health such as cardiac safety, dermatological health, immune control, reproductive health, the integrity of the gut barrier and oxidative stress.\n<\/p>\n

\nIn January 2021, Novozymes, a Denmark based biotechnology company acquired Microbiome Labs for an undisclosed amount. Microbiome Labs’ acquisition is a crucial step in expanding Novozymes’ Human Health platform, giving it exposure to a wide range of patented solutions as well as access to the firm’s network of health professionals. Microbiome Labs is a US-based probiotics company.\n<\/p>\n

\nMajor players in the microbiome market are<\/strong>\n<\/p>\n